Published 11 days ago • loading... • Updated 10 days ago

Novo Nordisk expands discounted Wegovy to all cash-paying U.S. customers

Novo Nordisk is expanding its savings program, offering Wegovy at a reduced price of $499 per month to all cash-paying customers in the U.S. At local pharmacies.
Novo Nordisk is cutting the price of Wegovy to $499 a month for cash-paying customers, down from $650, as part of an expanded savings program for uninsured patients.
The drug's list price was $1,349.02, marking a discount of over 60%.
The price cut follows increased competition from Eli Lilly, which also offers discounted weight-loss drugs.

Insights by Ground AI

Does this summary seem wrong?

11 Articles

All

Left

Center

Right

DNyuz

Lean Right

Novo Nordisk’s weight loss drug Wegovy is now cheaper for even more patients

Novo Nordisk (NVO-2.08%), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half for even more patients that pay without insurance. The Danish pharma giant announced today that it is expanding its savings program, offering Wegovy for $499 a month at all local pharmacies in the U.S. That marks a steep discount — more than 60% off the drug’s $1,349.02 list price. Previously, this reduced price was…

10 days ago

Read Full Article

The Motley Fool

Lean Left

Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped @themotleyfool #stocks $NVO $LLY $HIMS

There's a price war brewing in GLP-1 weight loss drugs, and now it's going global.

11 days ago·Alexandria, United States

Read Full Article

CNBC

Center

Novo Nordisk expands discounted Wegovy to all cash-paying U.S. customers

Until now, Novo Nordisk's weight-loss drug Wegovy was only available at the discounted price through its NovoCare Pharmacy program.

11 days ago·United States

Read Full Article

Quartz

Center

Novo Nordisk's weight loss drug Wegovy is now cheaper for even more patients

Novo Nordisk (NVO), the maker of the blockbuster drug Ozempic, is cutting the price of its weight loss drug by more than half for even more patients that pay without insurance.Read more...

11 days ago·United States

Read Full Article

Benzinga

Center

EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug - Mira Pharmaceuticals (NASDAQ:MIRA)

MIRA Pharmaceuticals signs letter of intent to acquire SKNY Pharmaceuticals, adding SKNY-1, a preclinical drug for weight loss and smoking cessation, to its portfolio.

11 days ago·New York, United States

Read Full Article